Entrada Therapeutics Q2 2023 Earnings Report

Entrada Therapeutics EPS Results

• Actual EPS: -$0.78
• Consensus EPS: -$0.43
• Beat/Miss: Missed by -$0.35
• One Year Ago EPS: N/A

Entrada Therapeutics Revenue Results

• Actual Revenue: $18.17 million
• Expected Revenue: $19.56 million
• Beat/Miss: Missed by -$1.39 million
• YoY Revenue Growth: N/A

Entrada Therapeutics Announcement Details

• Quarter: Q2 2023
• Date: 8/8/2023
• Time: N/A

Entrada Therapeutics (NASDAQ:TRDA), a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.